UK ABPI Suspends Novo Nordisk Over Code Breach
Novo Nordisk has been given a two-year suspension from membership of the Association of the British Pharmaceutical Industry for breaching the association’s code of practice.
You may also be interested in...
The company has been found in breach of the UK code once again for its work with pharmacists, although this time Novo Nordisk has escaped the heaviest censure.
Unprecedented demand for Wegovy in the US, together with issues experienced at the contract manufacturing site that resulted in supply shortages, led to Novo Nordisk having to wait some time for NICE to publish its final recommendation for the drug’s use on the National Health Service in England.
Plans for a new kind of drug pricing scheme put forward by the UK ABPI are intended to put the life sciences sector “back on the path for future growth,” the association says.